ProPhase Labs (PRPH) Competitors $0.61 +0.01 (+2.12%) Closing price 04:00 PM EasternExtended Trading$0.62 +0.01 (+1.84%) As of 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRPH vs. RPTX, ARTV, VTVT, UNCY, BYSI, VNRX, ALTS, HYPD, INCR, and GANXShould you be buying ProPhase Labs stock or one of its competitors? The main competitors of ProPhase Labs include Repare Therapeutics (RPTX), Artiva Biotherapeutics (ARTV), vTv Therapeutics (VTVT), Unicycive Therapeutics (UNCY), BeyondSpring (BYSI), VolitionRx (VNRX), ALT5 Sigma (ALTS), Hyperion DeFi (HYPD), InterCure (INCR), and Gain Therapeutics (GANX). These companies are all part of the "pharmaceutical products" industry. ProPhase Labs vs. Its Competitors Repare Therapeutics Artiva Biotherapeutics vTv Therapeutics Unicycive Therapeutics BeyondSpring VolitionRx ALT5 Sigma Hyperion DeFi InterCure Gain Therapeutics Repare Therapeutics (NASDAQ:RPTX) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends. Do insiders and institutionals have more ownership in RPTX or PRPH? 85.1% of Repare Therapeutics shares are held by institutional investors. Comparatively, 9.5% of ProPhase Labs shares are held by institutional investors. 11.5% of Repare Therapeutics shares are held by company insiders. Comparatively, 9.6% of ProPhase Labs shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer RPTX or PRPH? Repare Therapeutics currently has a consensus price target of $4.50, indicating a potential upside of 147.25%. Given Repare Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Repare Therapeutics is more favorable than ProPhase Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Repare Therapeutics 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has more risk and volatility, RPTX or PRPH? Repare Therapeutics has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.62, indicating that its stock price is 162% less volatile than the S&P 500. Which has preferable earnings and valuation, RPTX or PRPH? ProPhase Labs has higher revenue and earnings than Repare Therapeutics. Repare Therapeutics is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRepare Therapeutics$250K312.74-$84.69M-$2.58-0.71ProPhase Labs$6.77M3.73-$53.36M-$1.26-0.48 Is RPTX or PRPH more profitable? Repare Therapeutics' return on equity of -78.25% beat ProPhase Labs' return on equity.Company Net Margins Return on Equity Return on Assets Repare TherapeuticsN/A -78.25% -66.85% ProPhase Labs N/A -262.42%-76.48% Does the media refer more to RPTX or PRPH? In the previous week, Repare Therapeutics had 2 more articles in the media than ProPhase Labs. MarketBeat recorded 2 mentions for Repare Therapeutics and 0 mentions for ProPhase Labs. Repare Therapeutics' average media sentiment score of 0.51 beat ProPhase Labs' score of 0.00 indicating that Repare Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Repare Therapeutics Positive ProPhase Labs Neutral SummaryRepare Therapeutics beats ProPhase Labs on 11 of the 15 factors compared between the two stocks. Get ProPhase Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRPH vs. The Competition Export to ExcelMetricProPhase LabsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.25M$2.67B$6.10B$10.53BDividend YieldN/A53.56%5.51%4.66%P/E Ratio-0.4823.8685.6826.85Price / Sales3.73613.35584.82185.94Price / CashN/A28.3526.3031.10Price / Book2.435.5913.256.72Net Income-$53.36M$32.78M$3.30B$276.44M7 Day Performance32.77%5.24%4.70%3.13%1 Month Performance71.26%10.87%8.43%10.21%1 Year Performance-75.39%-1.45%88.01%40.35% ProPhase Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRPHProPhase Labs0.4397 of 5 stars$0.61+2.1%N/A-75.8%$25.25M$6.77M-0.48130Gap UpRPTXRepare Therapeutics2.8159 of 5 stars$1.74+3.0%$4.50+158.6%-50.9%$72.60M$53.48M-0.67180News CoveragePositive NewsARTVArtiva Biotherapeutics3.4259 of 5 stars$2.92-1.4%$17.00+482.2%-81.5%$72.30M$250K0.0081Positive NewsVTVTvTv Therapeutics1.7133 of 5 stars$22.88+2.5%$35.50+55.2%+54.8%$71.33M$1.02M-7.339UNCYUnicycive Therapeutics2.3265 of 5 stars$4.15+3.2%$57.00+1,273.5%+23.1%$71.00MN/A-1.019BYSIBeyondSpringN/A$1.74-1.1%N/A-24.9%$70.99M$1.75M0.0080Positive NewsVNRXVolitionRx2.2769 of 5 stars$0.62+3.0%$3.50+461.8%-27.0%$67.03M$1.32M-1.7380Gap UpALTSALT5 Sigma0.1071 of 5 stars$2.82-9.0%N/A+63.9%$66.99M$12.53M0.00170News CoverageShort Interest ↑HYPDHyperion DeFi0.5851 of 5 stars$10.24+7.0%$2.00-80.5%-73.1%$66.60M$60K-0.1840INCRInterCure1.0953 of 5 stars$1.56+6.8%N/A-15.0%$66.53M$238.85M0.00350Positive NewsShort Interest ↓Gap UpHigh Trading VolumeGANXGain Therapeutics3.0455 of 5 stars$1.81+1.1%$8.00+342.0%+22.0%$64.35M$50K-2.8720News CoverageAnalyst ForecastOptions VolumeGap Up Related Companies and Tools Related Companies RPTX Competitors ARTV Competitors VTVT Competitors UNCY Competitors BYSI Competitors VNRX Competitors ALTS Competitors HYPD Competitors INCR Competitors GANX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRPH) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProPhase Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
